10 pharma executives
At Pfizer, GSK, Novartis, Merck, Jazz Pharmaceuticals, Organon and Daiichi Sankyo, the pharma executives here hold the chief executive title today, while the other three hold the top science and R&D posts at Eli Lilly and Teva and the presidency of Bayer U.S. Pharmaceuticals. Two of the chief executives served earlier as chief financial officers and one held manufacturing and supply roles, so the group suits questions on pipeline bets, launch spending and supply planning.
Professionals to explore
Albert Bourla
LinkedInExperience: Chief Executive Officer · Pfizer
Albert Bourla has been Chief Executive Officer of Pfizer since 2019 and Chairman of the Board since 2020. Bourla's other Pfizer roles include Chief Operating Officer (2018), Group President, Pfizer Innovative Health (2014-2017) and President & General Manager, Established Products (2010-2014), and Bourla joined the company in 1993. Those roles make Bourla a fit for questions on weighing new medicines against established product lines.
Is this you? Claim your profile and get paid for calls.
Daniel Skovronsky
LinkedInExperience: Executive Vice President and Chief Scientific and Product Officer · Eli Lilly and Company
Executive Vice President and Chief Scientific and Product Officer at Eli Lilly and Company since 2025, Daniel Skovronsky was Executive Vice President and Chief Scientific Officer there (2018-2025) and Senior Vice President, Clinical and Product Development (2014-2018). In Skovronsky's own words, the job is leading teams that turn scientific ideas into medicines, serving as president of Lilly Research Laboratories and overseeing global business development. Skovronsky also was Founder and Chief Executive Officer of Avid Radiopharmaceuticals, Inc. (2005-2012).
Is this you? Claim your profile and get paid for calls.
Eric A. Hughes, MD, PhD
LinkedInExperience: Executive Vice President Global R&D and Chief Medical Officer · Teva Pharmaceuticals
Since 2022, Eric A. Hughes, MD, PhD has been Executive Vice President Global R&D and Chief Medical Officer at Teva Pharmaceuticals, overseeing about 4,000 professionals who develop generic, biosimilar and innovative medicines. Hughes was Senior Vice President, Clinical Development and Translational Medicine at Vertex Pharmaceuticals (2021-2022) and Global Head, Clinical Development and Analytics at Novartis (2020-2021). Hughes fits questions on balancing generics, biosimilars and new medicines in one pipeline.
Is this you? Claim your profile and get paid for calls.
Joseph Morrissey
LinkedInExperience: Chief Executive Officer · Organon
Organon named Joseph Morrissey Chief Executive Officer in 2026; Morrissey had been Interim Chief Executive Officer (2025-2026) and Executive Vice President, Head of Manufacturing and Supply (2021-2025) there. At Merck, Morrissey held Head of Manufacturing and Supply, Organon & Co. (2020-2021) and Senior Vice President, Global Animal Health Manufacturing Operations (2017-2020). Those manufacturing roles make Morrissey the pick here for supply risk questions.
Is this you? Claim your profile and get paid for calls.
Ken Keller
LinkedInExperience: Chairman of the Board, President and CEO and Head of the Global Oncology Business Unit · Daiichi Sankyo
Ken Keller has been Chairman of the Board, President and CEO and Head of the Global Oncology Business Unit at Daiichi Sankyo since 2014. Keller's other roles include President and CEO of American Regent, Inc. (2016-2021), Executive Vice President and Chief Operating Officer at Spectrum Pharmaceuticals, Inc. (2012-2014) and Vice President and General Manager, Bone Health at Amgen (2010-2012). The oncology unit role suits questions on where to place bets within one therapeutic area.
Is this you? Claim your profile and get paid for calls.
Luke Miels
LinkedInExperience: Chief Executive Officer · GSK
GSK's Chief Executive Officer since 2026, Luke Miels served there as CEO Designate (2025) and Chief Commercial Officer (2017-2025). At Roche, Miels was Regional Head Asia Pacific (2009-2014) and VP Head Metabolism & Anemia Global Marketing (2006-2009). Eight years as GSK's Chief Commercial Officer make Miels a strong voice on how commercial teams shape which markets get investment.
Is this you? Claim your profile and get paid for calls.
Nelson Ambrogio
LinkedInExperience: President Bayer U.S. Pharmaceuticals · Bayer
Nelson Ambrogio holds the title President Bayer U.S. Pharmaceuticals (since 2026). Ambrogio's other Bayer roles are President of Radiology (2024-2026), SVP, General Manager Oncology US (2021-2024), Senior Vice President & General Manager, Women's Healthcare US (2019-2021) and General Manager Australia New Zealand (2015-2019). That spread of franchises fits questions on how a U.S. pharmaceutical business weighs oncology, radiology and women's health.
Is this you? Claim your profile and get paid for calls.
Renee Gala
LinkedInExperience: President and Chief Executive Officer · Jazz Pharmaceuticals
At Jazz Pharmaceuticals, Renee Gala has been President and Chief Executive Officer since 2025, after serving as President and Chief Operating Officer (2023-2025) and EVP and Chief Financial Officer (2020-2023). Gala also sits on the Dexcom board (since 2025) and was a Board Member at Gossamer Bio (2018-2024). Finance, operating and chief executive roles at one company make Gala a fit for questions on how funding decisions change as responsibilities widen.
Is this you? Claim your profile and get paid for calls.
Rob Davis
LinkedInExperience: Chairman and Chief Executive Officer · Merck
Rob Davis is Chairman and Chief Executive Officer of Merck (since 2022), having served as Chief Executive Officer and President (2021-2022) and President (2021). Davis was Executive Vice President, Global Services and Chief Financial Officer (2016-2021) and Executive Vice President and Chief Financial Officer (2014-2016) at Merck. Seven years as CFO make Davis a good pick for questions on how capital is allocated across a pipeline.
Is this you? Claim your profile and get paid for calls.
Vas Narasimhan
LinkedInExperience: Chief Executive Officer · Novartis
Chief Executive Officer of Novartis since 2018, Vas Narasimhan was Global Head of Drug Development and Chief Medical Officer there (2016-2018) and Global Head, Development (2014-2016 and 2012-2014). Narasimhan is a physician who worked briefly at McKinsey before joining Novartis in 2005. The development roles suit questions on how pipeline priorities get set when a drug developer becomes chief executive.
Is this you? Claim your profile and get paid for calls.
Choose the right perspective
For portfolio and capital allocation questions, the seven chief executives are the natural pick, with Rob Davis and Renee Gala adding a finance view from their CFO years. Daniel Skovronsky and Eric A. Hughes, MD, PhD hold the science and R&D seats for questions about what enters the clinic; Joseph Morrissey's manufacturing and supply roles suit supply questions, and Nelson Ambrogio's Bayer posts span oncology, radiology and women's healthcare.
Questions to take into the conversation
- 01When a late-stage program reads out mixed data, how do you decide whether to fund Phase 3, partner it or stop?
- 02How do you split commercial investment between a new launch and the established brands that still carry revenue?
- 03What manufacturing and supply questions do you need answered before committing to a new product or market?
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot; roles marked former had ended by then. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.